60 Degrees Pharmaceuticals, Inc.

NasdaqCM SXTP

60 Degrees Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 147.90 K

60 Degrees Pharmaceuticals, Inc. Total Non-Current Liabilities is USD 147.90 K for the quarter ending September 30, 2024, a -3.08% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • 60 Degrees Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 152.59 K, a -99.30% change year over year.
  • 60 Degrees Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 21.85 M.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
NasdaqCM: SXTP

60 Degrees Pharmaceuticals, Inc.

CEO Dr. Geoffrey Stuart Dow
IPO Date July 12, 2023
Location United States
Headquarters 1025 Connecticut Avenue NW
Employees 3
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

StockViz Staff

January 15, 2025

Any question? Send us an email